Personalis Inc. Receives Buy Rating from Michael Matson Due to Strong Financial Performance and Positive Outlook

Analyst Michael Matson of Needham reiterated a Buy rating on Personalis (PSNL – Research Report), retaining the price target of $7.00.

Michael Matson has given his Buy rating due to a combination of factors including Personalis’s strong financial performance and positive outlook. The company exceeded expectations in both revenue and earnings per share for the first quarter of 2025, which has been a significant factor in the positive assessment. Additionally, the revenue growth showed a marked improvement, driven by increases in biopharma and VA MVP revenues, despite a decline in enterprise sales.
Another critical factor in the Buy rating is the substantial growth in the company’s molecular test volume, which rose by 52% compared to the previous quarter. Furthermore, Personalis has maintained its guidance for 2025 and expects favorable reimbursement decisions for its NeXT Personal product. These elements collectively contribute to a positive outlook for the company’s future performance, justifying the Buy rating.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.